Abstract:Ulcerative colitis (UC) is a chronic and nonspecific intestinal inflammatory disease, which may increase the risk of colon cancer. Andrographolide is a main active component of Andrographis paniculata. The anti-inflammatory ability of andrographolide suggested its potential therapeutic effect against UC. In the present study, elevated serum concentrations of proinflammatory factors, including (TNF)-α, interleukin (IL)-1β, IL-6 and IL-23, as well as increased percentages of Th17 cells (IL-17+CD4+ cells) in CD4+ cells were detected in UC patients compared to that in healthy donors. These data suggested that Th17 immune responses may involve in the pathogenesis of UC. Experimental colitis mouse model was then established. The results of hematoxylin and eosin staining demonstrated the therapeutic effect of andrographolide on colitis. Enzyme-linked immunosorbent assay (ELISA), flow cytometry and western blotting analyses showed that andrographolide could decreased the levels of proinflammatory factors TNF-α, IL-1β, IL-6 and IL-17A in the serum and in the colon tissues, reduced the percentages of Th17 cells in CD4+ cells, and suppressed the levels of IL-23, IL-17A, ROR-γt (key transcription factor of Th17 cells) and p-STAT3 in the colon tissues. Further, peripheral blood mononuclear cells (PBMCs) were isolated from UC patients and treated with various concentrations of andrographolide (0, 10, 20 and 30 μg/ml). Andrographolide also showed inhibitory effects on the levels of proinflammatory factors, the percentages of Th17 cells and the expression of relative proteins. Similar results were obtained in lipopolysaccharide-treated normal PBMCs. These data suggested that andrographolide may inhibit Th17 immune response via STAT3 signaling. In conclusion, we demonstrated that andrographolide inhibited the activity of IL-23/IL-17 axis and down-stream pro-inflammatory factors so as to suppress inflammation response, resulting in the relieving of UC.

Andrographolide Inhibits Expression of TNF-α and IL-12 in Activated Macrophages

Andrographolide Inhibits the Production of TNF-α and Interleukin-12 in Lipopolysaccharide-Stimulated Macrophages: Role of Mitogen-Activated Protein Kinases

Andrographolide Inhibits Extracellular Signal-Regulated Kinase 1/2 Signaling Pathway in Activated Macrophages

Synthesis of Andrographolide Derivatives and Their TNF-α and IL-6 Expression Inhibitory Activities

Immunomodulatory Activity of Andrographolide on Macrophage Activation and Specific Antibody Response

Effects of andrographolide on NF-κB signaling pathway in human lung adenocarcinoma A549 cells

Andrographolide inhibits the activation of NLRP3 inflammasome in patients with COPD

CHP1002, a Novel Andrographolide Derivative, Inhibits Pro-Inflammatory Inducible Nitric Oxide Synthase and Cyclooxygenase-2 Expressions in RAW264.7 Macrophages Via Up-Regulation of Heme Oxygenase-1 Expression.

Andrographolide attenuates inflammation by inhibition of NF-kappa B activation through covalent modification of reduced cysteine 62 of p50

Effect of andrographolide on inflammation suppression of RAW264.7 cell induced by lipopolysaccharide

Inhibition of TNF-α-Induced Inflammation by Andrographolide via Down-Regulation of the PI3K/Akt Signaling Pathway

Andrographolide Presents Therapeutic Effect on Ulcerative Colitis Through the Inhibition of IL-23/IL-17 Axis.

Effect of Andrographolide on Expressions of Inflammatory Cells, Interleukin-12 and Interleukin-13 in Bronchoalveolar Larage Fluid of Asthmatic Mice Model

Effects of Andrographolide on the Expression of IL-18 Related Cytokines in Human PBMC/PBM

TMT-Based Quantitative Proteomics Reveals the Targets of Andrographolide on LPS-induced Liver Injury

Andrographolide Derivative AL-1 Ameliorates TNBS-induced Colitis in Mice: Involvement of NF-кB and PPAR-γ Signaling Pathways.

Andrographolide suppresses thymic stromal lymphopoietin in phorbol myristate acetate/calcium ionophore A23187-activated mast cells and 2,4-dinitrofluorobenzene-induced atopic dermatitis-like mice model

Andrographolide inhibits melanoma tumor growth by inactivating the TLR4/NF-κB signaling pathway

[Effects of Andrographolide on the Expression of Eosinophil Granulocytes and Possible Mechanisms].

Andrographolide suppresses proliferation of human colon cancer SW620 cells through the TLR4/NF-κB/MMP-9 signaling pathway.

Andrographolide inhibits human hepatoma-derived Hep3B cell growth through the activation of c-Jun N-terminal kinase.